Karo Financial Statements From 2010 to 2024
| KARBFDelisted Stock | USD 5.25 0.00 0.00% |
Check Karo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karo main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Karo financial statements analysis is a perfect complement when working with Karo Pharma Valuation or Volatility modules.
Karo |
Karo Pharma AB Company Return On Asset Analysis
Karo Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Karo Pharma Return On Asset | 0.0017 |
Most of Karo Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Karo Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Karo Pharma AB has a Return On Asset of 0.0017. This is 100.02% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is 101.21% lower than that of the firm.
Karo Pharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Karo Pharma's current stock value. Our valuation model uses many indicators to compare Karo Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Karo Pharma competition to find correlations between indicators driving Karo Pharma's intrinsic value. More Info.Karo Pharma AB is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Karo Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Karo Pharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Karo Pharma's earnings, one of the primary drivers of an investment's value.About Karo Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Karo Pharma income statement, its balance sheet, and the statement of cash flows. Karo Pharma investors use historical funamental indicators, such as Karo Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Karo Pharma investors may use each financial statement separately, they are all related. The changes in Karo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Karo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Karo Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Karo Pharma. Please read more on our technical analysis and fundamental analysis pages.
Karo Pharma AB develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. Karo Pharma AB was incorporated in 1987 and is headquartered in Stockholm, Sweden. Karo Pharma is traded on OTC Exchange in the United States.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Karo Pharma AB information on this page should be used as a complementary analysis to other Karo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Karo Pink Sheet
If you are still planning to invest in Karo Pharma AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karo Pharma's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |